The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder by Chi-Chen Lu et al.
Lu et al. BMC Complementary and Alternative Medicine 2013, 13:44
http://www.biomedcentral.com/1472-6882/13/44RESEARCH ARTICLE Open AccessThe investigation of a traditional Chinese
medicine, Guizhi Fuling Wan (GFW) as an
intravesical therapeutic agent for urothelial
carcinoma of the bladder
Chi-Chen Lu1,4,5, Mei-Yi Lin1, Syue-Yi Chen2, Cheng-Huang Shen2,3, Lih-Geeng Chen6, Hsiao-Yen Hsieh2,4,5,
Michael WY Chan4,5* and Cheng-Da Hsu2,4*Abstract
Background: The high risk of recurrence faced by patients with bladder cancer has necessitated the administration
of supplemental intravesical chemotherapy; however, such treatments often result in severe side effects. As a result,
novel intravesical agents with enhanced efficacy and minimal toxicity are urgently required for the treatment of
bladder cancer.
Methods: Guizhi Fuling Wan (GFW) is a traditional Chinese medicine shown to inhibit the growth of hepatocellular
carcinoma. This study evaluated the growth inhibition of GFW using normal human urothelial cells and bladder
cancer cells; the efficacy of GFW treatment was further compared with mitomycin C, epirubicin, and cisplatin. We
also examined the progression of cell cycle and apoptosis in bladder cancer cells in response to GFW treatment.
CCK-8 was employed to analyze cell viability and flow cytometry was used to study the cell cycle and apoptosis.
The mechanisms underlying GFW-induced cell cycle arrest were determined by Western blot analysis.
Results: Our data demonstrate the potent inhibitory effect of GFW in the proliferation of bladder cancer cell lines,
BFTC 905 and TSGH 8301. GFW presented relatively high selectivity with regard to cancer cells and minimal toxicity
to normal urothelial cells. Our results also demonstrate that GFW interferes with cell cycle progression through the
activation of CHK2 and P21 and induces apoptosis in these bladder cancer cells.
Conclusions: Our results provide experimental evidence to support GFW as a strong candidate for intravesicle
chemotherapy against bladder cancer.Background
Urothelial carcinoma (UC) is the most common cancer
of the urinary tract [1] and the fourth most common
malignancy in the U.S. [2]. The most common histo-
logical type of UC is transitional cell carcinoma (TCC),
which is originated from the urothelial lining of the
urinary tract [3]. Although UC may occur anywhere in
the urinary tract, it generally originates in the urinary
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reproduction in any medium, provided the ormuscle invasive disease have a high risk of recurrence
[5], necessitating the use of intravesical chemotherapy or
Bacillus Calmette-Guerin (BCG) as a supplement to
transurethral resection (TUR) [6]. Unfortunately, intravesical
chemotherapy, such as mitomycin C or thiotepa, com-
monly produce severe side effects, including urinary
frequency, urinary urgency, cystitis, and hematuria [7].
Thus, novel intravesical agents with proven efficacy and
minimal toxicity are urgently required for the treatment
of bladder cancer.
Guizhi Fuling Wan (GFW) is a well-known traditional
Chinese herbal formula, comprising five herbs including
Cinnamomi Ramulus, Poria Cocos, Paeoniae Radix Rubra,
Persicae Semen, and Moutan Cortex [8]. It has been usedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stasis [9-11]. Due to its sedative, analgesic, and anti-
inflammatory effects, GFW has also been used in the
treatment of various diseases. For example, GFW has
been shown to inhibit the growth of hepatocellular car-
cinoma [12,13] and cervical cancer [14]. However, the
effect of GFW on urothelial carcinoma has never been
explored. This study compared the effects of GFW with
various other chemotherapeutic agents in the growth of
normal human urothelial cell and two cancer cell lines.
The effects of these agents on cell cycle progression and
apoptosis in urothelial cancer cells were also compared.
Finally, we sought to reveal the underlying mechanisms
involved in cell cycle arrest induced by GFW.
Methods
Preparation of agents and cell cultures
GFW herbal extract (batch No. 221141) was purchased
from Sun Ten Pharmaceutical Co., Ltd. (Taichung City,
Taiwan) and validated using HPLC as outlined in the
Supplemental Experimental Procedures (see Additional
file 1). GFW and Ramulus Cinnamomi (otherwise known
as Guizhi) (Sun Ten Pharmaceutical, Taiwan, ROC) were
dissolved in ddH2O and filtered using a 0.22 micron
filter at 220 mg/ml and 129.4 mg/ml, respectively. The
concentrations of these stock solutions were then
confirmed by weighing after lyophilization. Mitomycin-C
(Kyowa Hakko Kirin Co., Tokyo, Japan), Epirubicin (Actavis
Italy S.P.A., Milano, Italy) and Cisplatin (ABIC Biological
Laboratories Ltd., Netanya, Israel) were dissolved in normal
saline buffer at 1 mg/ml to provide stock solutions
which were then diluted with cell culture medium to
desired concentrations ranging from 0.0025 to 0.08 mg/ml.
Human bladder papillary transitional cells, BFTC 905,
and bladder carcinoma cells, TSGH 8301 (Food Industry
Research and Development Institute, Taiwan, ROC) as
well as primary normal urothelial cells, HUC 4449
(ScienCell Research Laboratories, Carlsbad, CA, USA)
were used as cell models. BFTC 905 and TSGH 8301
were cultured in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), 100 units/ml penicillin and
100 μg/ml streptomycin. HUC 4449 was cultured in
urothelial cell medium (ScienCell Research Laboratory,
Carlsbad, CA, USA) supplemented with 10% FBS, 100
units/ml penicillin and 100 μg/ml streptomycin. All cell
lines were cultured at 37°C under a humidified atmos-
phere containing 5% CO2. All studies involving human
cell lines were conformed to the Helsinki Declaration
and approved by the Institutional Review Boards of the
Chia-Yi Christian Hospital (reference number: 099078).
Cell viability assay
BFTC 905, TSGH 8301 and HUC 4449 were initially
seeded in 96-well plates at 1 × 104 cells per well andcultured for 24 h. The cells were subsequently starved
in medium supplemented without FBS for 24 h, and then
treated with the agents of interest at various concentrations
for 24 h. Cell viability was then determined using the
Cell Counting Kit-8 (CCK-8) (SIGMA, Switzerland), in
accordance with the manufacturer’s protocol. In brief,
the assay was performed using WST-8, [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5- (2, 4-disulfophenyl)-2H-
tetrazolium, monosodium salt], which can be bio-reduced
by cellular dehydrogenases to an orange formazan
product, which is then dissolved in cell culture medium.
The production of formazan occurs only in living cells
at a rate proportional to the number of living cells. After
incubating the cells with CCK-8, the light absorbance
of the culture medium in each well was measured at
450/655 nm using Microplate reader Model 680 (BIO-
RAD). The cell viability rate, compared to the control (un-
treated cells), was calculated using the following equation.
Viability %ð Þ ¼ 100 Absorbance of treated group
=Absorbance of untreated group
The percentage of viability versus the concentration of
a given agent was used to calculate the concentration
that would return cell viability of 50% (IC50).
The selectivity index (SI), cytotoxic selectivity of the
agent against cancer cells, versus normal cells [15], was
calculated from the IC50 as follows:
SI ¼ IC50 of the given agent in normal cells
=IC50 of the given agent in cancer cells
Cell cycle analysis
BFTC 905, TSGH 8301, and HUC 4449 were initially
seeded in 6-well plates at 2 × 105 cells per well and
cultured for 24 h. The cells were then starved in medium
supplemented without FBS for 24 h, and then treated
with 0.5 and 1 mg/ml of GFW for 24 h. Following treat-
ment with GFW, single-cell suspensions were prepared
using trypsinization and resuspension in PBS and then
fixed with methanol at 4°C overnight. The fixed cells
were rehydrated and washed twice with PBS before
being stained via incubation with 5 μg /ml propidium
iodide (SIGMA, St. Gallen, Switzerland) and 1 mg/ml
RNase A for 30 min at room temperature. The cells were
then analyzed using a BD FACSCanto II flow cytometer
(BD Biosciences, Franklin Lakes, NJ, USA) using Mod
Fit LT™ 3.3 software.
Apoptosis analysis
Cell apoptosis was analyzed using the Annexin V-FITC
Apoptosis Detection Kit (BioVision, Mountain View, CA,
USA), in accordance with the manufacturer’s protocol. In
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were seeded in 6-well plates at 2 × 105 cells per well
and cultured for 24 h. They were then treated with 0.5
or 1 mg/ml of GFW for 24 h. Single-cell suspensions
were then prepared by trypsinization and resuspended
in 500 μl of binding buffer supplied by the manufac-
turer. The cell suspensions were combined with 5 μl of
annexin V-FITC and 5 μl of propidium iodide and
incubated at room temperature for 5 min in the dark,
before being analyzed using a BD FACSCanto II flow
cytometer (BD Biosciences, Franklin Lakes, NJ, USA)
using Mod Fit LT™ 3.3 software.
Western blot analysis
BFTC 905 and TSGH 8301 were seeded in 6-well plates at
2 × 105 cells per well and cultured for 24 h. The cells were
starved in medium supplemented without FBS for 24 h,
and then treated with 2 mg/ml of GFW for various
durations. Cell total proteins were extracted and identified
using a Bio-Rad protein assay (Bio-Rad, Hercules, CA)
with bovine serum albumin (BSA) as a standard. Each lys-
ate (10 μg) was resolved on denaturing polyacrylamide
gels and transferred electrophoretically to a PVDF transfer
membrane. After blocking with 3% blocker (Bio-Rad) in
TBS-Tween 20 (TBST), the membranes were incubated
with primary antibodies [CHK2, 1 : 1000; Phospho-CHK2
(Thr68), 1 : 1000 and p21, 1 : 1000 (Cell Signaling,
Danvers, MA, USA)] at room temperature for 2 h.
Immunoreactive proteins were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies for 1 h
at room temperature. After being washed with TBST, the
reactants were developed using the enhanced chemilu-
minescence kit (GE Healthcare Biosciences) and identified
using the BioSpectrum 800 system (UVP).
Statistical analysis
The data were expressed as either mean ± SEM or a
percentage, relative to the untreated control. Data dis-
crepancies between the treated and untreated control
groups were analyzed using one way ANOVA followed
by Dunnett’s test. Statistical analysis was considered
significant if P is less than 0.01 and within the 99.9%
confidence interval.
Results
HPLC analysis of Guizhi Fuling Wan (GFW)
Guizhi Fuling Wan is composed of five Chinese herbs,
including Poria cocos, for which no accepted water-
soluble bioactive component is currently available. The
bioactive components of Cinnamomi Ramulus, Paeoniae
Radix Rubra, Persicae Semen, and Moutan Cortex are
cinnamaldehyde, paeoniflorin, amygdalin, and paeonol,
respectively. The structural variety of these four compounds
produces various absorption wavelengths (see Additionalfile 1: Figure S1). A photodiode array detector provided
simultaneous detection of the compounds as follows: amyg-
dalin (215 nm), paeoniflorin (232 nm), cinnamaldehyde
(280 nm), and paeonol (275 nm) (Figure 1A). The cali-
bration equations and correlation coefficients revealed
linear relationships between the peak areas and concen-
trations (see Additional file 1: Table S1). The relative stand-
ard deviation (RSD) of these four compounds in GFW
fell between 1.54-3.27% (intra-day) and 1.17-2.34%,
(inter-day) (Table 1), indicating the high degree of repro-
ducibility associated with this method. The contents of
the compounds in GFW were as follows: amygdalin
(11.53 mg/g), paeoniflorin (30.26 mg/g), cinnamaldehyde
(0.10 mg/g), and paeonol (0.28 mg/g) (Table 1, Figure 1B).
Maximum tolerated dosage of GFW in normal urothelial
cells
A fundamental requirement of intravesical agents is min-
imal cytotoxicity toward normal cells. To determine the
maximum dosage of GFW that normal urothelial cells
could tolerate, normal human urothelial HUC 4449 cells
were treated with various concentrations of GFW and its
major component, Ramulus Cinnamomi (Guizhi). The
non-toxic effects of Guizhi have been demonstrated in
MRC-5 normal lung epithelial cells [16]; therefore, we
selected Guizhi as a negative control for this study.
According to CCK-8 assay, GFW and Guizhi caused
significant death (p<0.01) of HUC 4449 cells at con-
centrations of 4 mg/ml and 8 mg/ml, respectively,
compared to the untreated control (Figure 2). This
suggests that GFW and Guizhi have cytotoxic effects
on normal urothelium only at high concentrations. We
therefore calculated that a concentration of 2 mg/ml
would be the maximum safe dose that normal urothelial
cells could withstand. This value was applied to all subse-
quent experiments dealing with cell cycle and apoptosis.
Cytotoxic effects of GFW, cisplatin, epirubicin, and
mitomycin-C on normal urothelial cells and bladder
cancer cell lines
Next, we performed an in vitro cell viability assay to
compare the cytotoxicity of GFW with traditional
chemotherapeutic agents (mitomycin C, epirubicin, and
cisplatin) in normal urothelial and cancer cell lines.
Compared with the untreated control, the CCK-8 assay
revealed that the cytotoxicity of GFW to TSGH 8301
and BFTC 905 urothelial cancer cells is comparable to
that of the three other chemotherapeutic agents with
different IC50 values (P< 0.001, one-way ANOVA) (Table 2
and Figure 3). Traditional chemotherapeutic agents have
much lower IC50 towards TSGH 8301 and BFTC 905 can-
cer cells; however, even such low doses are toxic to normal
urothelial cells (Table 2 and Figure 3). Conversely, GFW
is only toxic towards cancer cells, demonstrating a high
Figure 1 HPLC analysis: (A) HPLC chromatograms of (1) amygdalin, (2) paeoniflorin, (3) cinnamaldehyde, and (4) paeonol detected at
(a) 215 nm, (b) 232 nm, (c) 280 nm, (d) 275 nm; (B) HPLC chromatograms of (1) amygdalin, (2) paeoniflorin, (3) cinnamaldehyde, and
(4) paeonol in GFW detected at (a) 215 nm, (b) 232 nm, (c) 280 nm, (d) 275 nm.
Lu et al. BMC Complementary and Alternative Medicine 2013, 13:44 Page 4 of 10
http://www.biomedcentral.com/1472-6882/13/44selectivity index (SI) value toward TSGH 8301 cells
(8.35) and BFTC 905 cells (19.98). The SI values of
GFW are much higher than those of traditional
chemotherapeutic agents (Table 2).GFW arrests cell cycle progression in human bladder
cancer cells
We further investigated the effects GFW on the cell
cycle progression of urothelial cancer cells. Cell cycle
Table 1 Contents of amygdalin, paeoniflorin,
cinnamaldehyde, and paeonol in GFW with intra-day and
inter-day variability









Amygdalin 11.53 ± 0.18 1.54 11.56 ± 0.14 1.17
Paeoniflorin 30.26 ± 0.99 3.27 30.54 ± 0.69 2.24
Cinnamaldehyde 0.10 ± 0.00 2.40 0.10 ± 0.00 2.34
Paeonol 0.28 ± 0.01 2.69 0.28 ± 0.01 2.31
n=3 for intra-day, n=9 for inter-day.
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BFTC 905 cells with GFW at concentrations of 0.5 or
1 mg/ml for 24 h would result in significant cell cycle
arrest in the S phase (p < 0.01, Figure 4A); a concentra-
tion of 1 mg/ml resulted in a decrease in the number of
cells in the G2/M phase. In contrast, identical treatment
of TSGH 8301 cells with GFW resulted in significant
cell cycle arrest in the G2/M phase (p < 0.01, Figure 4B);
a concentration of 1 mg/ml resulted in a decrease in the
number of cells in G0/G1 phase.
These results suggest that GFW leads to the cell cycle
arrest at the G1 to S transition of BFTC 905 cells and
at the S to G2/M transition in TSGH 8301 cells. Accord-
ingly, the increase in the number of BFTC 905 cells in S
phase was significant at 0.5 and 1 mg/ml of GFW
(p<0.01), which correlates with a reduction in the num-
ber of cells in G2/M phase for these concentrations.
Conversely, the increase in the number of TSGH 8301
cells in G2/M phase was significant at 1 mg/ml of
GFW (p<0.01), which correlates with a reduction in
the number of cells in G0/G1 phase at this concentra-
tion (p<0.01). We also observed that, compared with theFigure 2 Cytotoxicity of GFW and Cinnamomi Ramulus against
normal human urothelial cell line, HUC 4449: Cells were initially
seeded in 96-well plates at 1 × 104 cells per well and cultured
for 24 h. The cells were subsequently starved in medium
supplemented without FBS for 24 h, and then treated with various
concentrations of agents for 24 h. Cell viability was detected using
the Cell Counting Kit-8 (CCK-8). Data are presented as mean ± SEM
(n=6). Significant differences from the no treatment control is
indicated by * * (p<0.01), as determined by one-way ANOVA and
Dunnett’s comparison test.control, treating BFTC 905 and TSGH 8301 with GFW
at a concentration of 1 mg/ml for 24 h induced cell
apoptosis, as evidenced by the presence of a subG1
population (Figure 4A, B).
To reveal the molecular mechanisms underlying the
effects of GFW, we investigated the expression of several
cell cycle regulatory proteins. Western blot results show
that the expression of phosphorylated Cell Cycle Check-
point Kinase-2 (CHK2) (Phospho-CHK2) increased sig-
nificantly following treatment with GFW for 2 h, which
was followed by a substantial increase in p21 in
BFTC905 cells after treatment for 4–6 h. In contrast,
only a slight, gradual increase was observed in the
p21 in TSGH8301 cells following treatment for 6 h
(Figure 4C). These results indicate that the CHK2/
P53/P21 pathway might be involved in the cell-cycle
arrest induced by GFW.
GFW-induced apoptosis in human bladder cancer cells
In light of the previous findings, we further investigated
the effect of GFW on the apoptosis of bladder cancer
cells. This represents the pharmaco-dynamic endpoint
of the actions of anticancer drugs [17] and an autono-
mous detachment process in which damaged cells are
removed, thereby avoiding the inflammatory response
normally associated with necrosis and the resulting
cytotoxicity to surrounding cells [18]. To investigate
the cytotoxic effects of GFW on apoptosis, we treated
bladder cancer cells with GFW at concentrations of 0.5
and 1 mg/ml for 24 h followed by analysis using the
AnnexinV-FITC staining method, as measured by flow
cytometry. Our results presented a dose-dependent in-
crease in apoptosis in cells treated with GFW with
significant apoptosis observed at a concentration of
1 mg/ml (Figure 5). Although the proportion of necrotic
cells increased proportionally under GFW treatment at
1 mg/ml (Q1), (Figure 5), we observed far fewer necrotic
cells than apoptotic cells. Taken together, these data indi-
cate that the major cytotoxic effect of GFW is the induc-
tion of apoptosis in bladder cancer cells.
Discussion
Inadequate outcomes associated with intravesical chemo-
therapy or Bacillus Calmette-Guerin (BCG) as a supple-
ment to TUR in the treatment of bladder cancer has
necessitated the development of alternative approaches to
chemo-therapy. Naturally occurring substances, such as
those found in traditional Chinese medicine, are promis-
ing candidates [19]. Recent studies have established the
effectiveness of TCM and naturally occurring substances
including Paeonia lactiflora Pall [20], Polyporus polysac-
charide [21,22], Lingzhi [23-25] and Cantharidin [26] for
chemoprevention as well as the chemotherapy of blad-
der cancer. However, the applicability of GFW as a
Table 2 Cytotoxic activities of agents
IC50 (mg/ml) ± standard deviation Selectivity index (SI
c)
HUC 4449 TSGH 8301 BFTC 905 TSGH 8301 BFTC 905
Guizhia Inactiveb Inactiveb Inactiveb
GFW 7.1191±0.9628 0.8524±0.1125 0.3564±0.0438 8.35 19.98
Cisplatin 0.0232±0.0069 0.0041±0.0013 0.0440±0.0020 5.66 0.52
Epirubicin 0.0054±0.001 0.0019±0.0002 0.0021±0.0001 2.84 2.57
Mitomycin-C 0.0102±0.002 0.0040±0.0005 0.0041±0.0002 2.55 2.49
Data are expressed as the mean of n replicates (n≧6).
a Non-anticancer agent and negative control.
b IC50 > 8 mg/ml is considered to be inactive.
c SI value > 3 indicates high selectivity [9].
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unknown. Previous studies have reported that GFW
can improve the condition of stagnated blood, which is
related to uterine myomas [11,27], varicocele [28],
therosclerosis [29], hypercholesteremia [29] and hot
flashes [30,31]. GFW has also demonstrated beneficial
effects toward articular inflammation and a protective
effect against endothelial dysfunction in patients with
rheumatoid arthritis [32]. In terms of its anti-cancer
effect, GFW has been shown to inhibit the growth of
hepatocellular carcinoma [12,13] and cervical cancer
[14]. Moutan Cortex, one of the major components of
GFW, has been shown to inhibit proliferation and in-
duce apoptosis of human hepatocellular carcinoma [33].
Our current study demonstrated that GFW can signifi-
cantly inhibit the proliferation of BFTC 905 cells, obtained
from a female grade III stage C bladder carcinoma [34]
and TSGH 8301 cells from a male grade II/stage A blad-
der carcinoma [35]. These results suggest that GFW has
similar cytotoxic effects in both of these bladder cancer
cell lines obtained from different sexes in different tumorFigure 3 Cytotoxicity of GFW, cisplatin, Epirubicin and mitomycin aga
cancer cell lines, TSGH 8301 and BFTC 905: Cells were initially seeded
The cells were subsequently starved in medium supplemented without FBS
24 h. Cell viability was detected using the Cell Counting Kit-8 (CCK-8). Data
no treatment control is indicated by * * (p<0.01), as determined by one-wastages. Our results also prove that GFW may be as effect-
ive as traditional chemotherapeutic agent, mitomycin C,
epirubicin, and cisplatin, in the treatment of bladder can-
cer. Furthermore, the high selectivity of GFW toward can-
cer cells greatly reduces the adverse side effects
associated with normal bladder urothelium. It is im-
portant to note that GFW presents a much higher
selectivity index (SI) value than the three mentioned
chemotherapeutic agents. Nevertheless, the high value
we obtained for GFW (SI >3) [15] warrants further
investigation. Intriguingly, according to the definition
of SI, the differential SI values of cisplatin to BFTC
905 cells (SI = 0.52) and TSGH 8301 cells (SI = 5.66)
suggests that this may involve a different mode of action
with regard to these cells [15,36].
Cell cycle analysis results indicate that GFW led to
cell cycle arrest in BFTC 905 in the S-phase, while cell
cycle arrest in TSGH 8301 occurred in G2/M phase
(Figures 4A and 4B). To elucidate the differential effects
of GFW on the cell cycle mechanism in these cells, we
investigated the expression status of various cell cycleinst normal human urothelial cell line, HUC 4449 and bladder
in 96-well plates at 1 × 104 cells per well and cultured for 24 h.
for 24 h and then treated with various concentrations of agents for
are presented as mean ±SEM (n=6). Significant differences from the
y ANOVA and Dunnett’s comparison test.
Figure 4 Effects of GFW on cell cycle of bladder cancer cells: (A) BFTC 905 and (B) TSGH 8301 cells. Cells were cultured in 6-well plates at
2 × 105 cells per well for 24 h, followed by starvation in medium without FBS for 24 h. The cells were then treated with 0, 0.5, or 1 mg/ml of
GFW for 24 h. Cells were harvested and stained using propidium iodide staining solution for 30 min in the dark and analyzed by flow cytometry.
Data are presented as the mean ± SEM (n = 4). Significant differences from the no treatment control are indicated by * * (p<0.01), as determined
by one-way ANOVA and Dunnett’s comparison test. (C) Western blots of phosphorylated CHK2, CHK2, and P21. The expression levels of
phosphorylated CHK2 increased in both BFTC 905 and TSGH 8301 cells following treatment with GFW for 2 h. A substantial increase in p21 was
observed in BFTC 905 cells following treatment with GFW for 4–6 h. A high basal level of P21 prior to treatment and a mild, gradual increase in
p21 level following treatment with GFW for 6 h was observed in TSGH 8301 cells.
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the phosphorylation of CHK2 followed by a substantial
expression of P21 (Figure 4C). Through phosphorylation,
CHK2 inhibits the function of protein phosphatases
CDC25A and CDC25C [37] resulting in the cell cycle
arrest at the G1/S and G2/M transitions, respectively
[37]. Activated CHK2 can also stabilize P53 [38-41],
which subsequently promotes the expression of P21
(WAF1) [42]. P21 can thus bind to CDK2-cyclin E
complex with a subsequent retardation of kinase activ-
ity resulting in the inhibition of cell cycle progression
in the S phase [43]. Moreover, P21 can suppress the
kinase activities of CDK2-cyclin A and CDK1-cyclin A
complexes, which are involved in the cell cycle progres-
sion in S and G2 phases, respectively [44]. On the other
hand, P21 also affects CDK1-cyclin B1 complex, which
is involved in the G2/M transition [44]. Accordingly,
we observed a robust increase in P21 in BFTC 905 cells
following GFW treatment for 4–6 h (Figure 4C). Cell
cycle arrest in the S phase suggests that the kinase activ-
ity of CDK2-cyclin E, CDK2-cyclin A, and CDK1-cyclinA complexes were inhibited (Figure 4A). However,
GFW appears to have a more complex effect on G2/M
cell cycle regulation in TSGH 8301 cells. We observed a
substantial basal level of P21 prior to treatment, such
that GFW treatment for 6 h provided only a slight, grad-
ual increase in P21 (Figure 4C). These results suggest
that a mild increase in P21 is ineffective in inhibiting
the kinase activity of CDK2-cyclin E, CDK2-cyclin A, or
CDK1-cyclin A complexes for S phase arrest. However,
the combined repression of CDC25A and CDC25C by
phospho-CHK2 and the partial inhibition of the kinase
activity of CDK2-cyclin E, CDK2-cyclin A, CDK1-cyclin
A, and CDK1-cyclin B1 could eventually lead to the
accumulation of cells in G2/M phase. Thus far, we
have only demonstrated the induction of CHK2 phos-
phorylation, which promotes the expression of P21 in
bladder cancer cells treated with GFW. This suggests
that cell cycle regulation following GFW treatment
might be caused by the profound expression of P21.
We suspect that GFW may cause very early genotoxic
stress responses in highly replicating cancer cells. These
Figure 5 Effects of GFW on apoptosis of bladder cancer cells: (A) BFTC 905 and (B) TSGH 8301 cells were treated with GFW at
concentrations of 0.5 and 1 mg/ml for 24 h. Cells were then analyzed by FACS to determine the relative% of apoptotic Annexin V/PI cells. The
lower left quadrant (Q3) represents viable cells; the upper left quadrant (Q1) represents necrotic cells; the lower right quadrant (Q4) represents
early apoptotic cells; and the upper right quadran (Q2) represents nonviable late apoptotic cells. The relative percentages of apoptotic cells
including early and late apoptotic cells were determined. Data are represented as mean ± SEM of two independent experiments performed in
triplicate. Significant differences from the no treatment control are indicated by * * (p<0.01), as determined by one-way ANOVA and Dunnett’s
comparison test.
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ase activity for the activation of cell cycle checkpoint
factors; however, further investigation is required.
Several studies have shown that cell cycle arrest may
lead to the induction of apoptosis [45,46]. Therefore, we
sought to determine whether GFW could induce apop-
tosis in bladder cancer cells. Although we observed that
BFTC 905 and TSGH 8301 cells underwent GFW-
induced apoptosis in both the early and late stages, most
of the apoptotic cells were in the late stage (Figure 5).
Treatment with 1 mg/ml of GFW resulted in signifi-
cantly higher levels of apoptosis than what was observed
in the untreated control group, indicating that GFW is a
potent inducer of apoptosis in both BFTC 905 and TSGH
8301 cells. However, flow cytometry analysis indicated
only a small proportion of necrotic cells in the samples
without GFW treatment. The proportion of necrotic cells
also underwent a slight increase following an increase
in the concentration of GFW. This may be due to apop-
totic pathway deficiencies [47] in these cancer cells, in
which the DNA damage response pathways may be
activated by transiently activating PARP1 to induce
necrotic cell death [48].Conclusions
Our results indicate that GFW is a potent inhibitor
of proliferation in BFTC 905 and TSGH 8301 bladdercancer cell lines. High selectivity to cancer cells and
minimal toxicity to normal urothelial cells makes it a
good candidate for intravesicle chemotherapy in blad-
der cancer; however, an in vivo animal study will be
required to further validate these results. We have also
demonstrated that GFW interferes with cell cycle progres-
sion via the activation of CHK2/P21 pathway and induces
apoptosis in these bladder cancer cells. GFW may act
through specific signaling to bypass defective apoptotic
pathways, thereby inducing selective necrotic cell death in
these bladder cancer cells. These results warrant further
experiments in vitro and in vivo to further elucidate the
anti-tumor effects of GFW in bladder cancer.Additional file
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